- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The renal urate transporter SLC17A1 locus: confirmation of association with gout ; volume:14 ; number:2 ; day:27 ; month:4 ; year:2012 ; pages:1-8 ; date:4.2012
Arthritis Research & Therapy ; 14, Heft 2 (27.4.2012), 1-8, 4.2012
- Creator
-
Hollis-Moffatt, Jade E.
- Contributor
-
Phipps-Green, Amanda J.
Chapman, Brett
Jones, Gregory T.
van Rij, Andre
Gow, Peter J.
Harrison, Andrew A.
Highton, John
Jones, Peter B.
Montgomery, Grant W.
Stamp, Lisa K.
Dalbeth, Nicola
Merriman, Tony R.
SpringerLink (Online service)
- DOI
-
10.1186/ar3816
- URN
-
urn:nbn:de:1111-2016050321585
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hollis-Moffatt, Jade E.
- Phipps-Green, Amanda J.
- Chapman, Brett
- Jones, Gregory T.
- van Rij, Andre
- Gow, Peter J.
- Harrison, Andrew A.
- Highton, John
- Jones, Peter B.
- Montgomery, Grant W.
- Stamp, Lisa K.
- Dalbeth, Nicola
- Merriman, Tony R.
- SpringerLink (Online service)
Other Objects (12)
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
Variation in serum urate levels in the absence of gout and urate lowering therapy
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
The relationship between ferritin and urate levels and risk of gout
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Transport mechanism and structural pharmacology of human urate transporter URAT1
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
Variation in serum urate levels in the absence of gout and urate lowering therapy
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
The relationship between ferritin and urate levels and risk of gout
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Transport mechanism and structural pharmacology of human urate transporter URAT1
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
Variation in serum urate levels in the absence of gout and urate lowering therapy
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
The relationship between ferritin and urate levels and risk of gout
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Transport mechanism and structural pharmacology of human urate transporter URAT1
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia